Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial to Investigate Linzagolix for the Treatment of Endometriosis-Associated Pain

Trial Profile

A Phase III Trial to Investigate Linzagolix for the Treatment of Endometriosis-Associated Pain

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Linzagolix (Primary)
  • Indications Endometriosis
  • Focus Registrational; Therapeutic Use
  • Sponsors ObsEva
  • Most Recent Events

    • 05 Oct 2018 New trial record
    • 28 Sep 2018 According to an ObsEva media release, following End-of-Phase 2 regulatory discussions, expected later this year, the company intends to initiate this phase III trial of linzagolix for the treatment of endometriosis-associated pain in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top